托伐普坦治疗AMI合并心力衰竭的疗效及对患者血清hs-CRP、NT-proBNP表达的影响

Efficacy of Tolvaptan in the Treatment of AMI Complicated with Heart Failure and its Effect on Serum hs-CRP and NT-proBNP Expression

目的探讨托伐普坦治疗急性心肌梗死(AMI)合并心力衰竭的疗效及对患者血清hs-CRP、NT-proBNP表达的影响。方法选取我院2016年8月~2018年9月收治的AMI合并心力衰竭患者84例,按随机数字表法分为对照组和观察组,各42例。对照组常规予以急救治疗与抗心衰药物治疗,观察组同时联合托伐普坦治疗,比较两组疗效及血清hs-CRP、NT-proBNP水平。结果观察组总有效率为95.24%,高于对照组的78.57%(P<0.05)。治疗1周后,观察组血清hs-CRP、NT-proBNP水平均低于对照组(P<0.05)。结论托伐普坦治疗急性心肌梗死合并心力衰竭有助于提高疗效,改善血清hs-CRP、NT-proBNP指标。

Objective To investigate the effect of tolvaptan on acute myocardial infarction(AMI)complicated with heart failure and its effect on serum hs-CRP and NT-proBNP expression.Methods 84 patients with AMI complicated with heart failure admitted to our hospital from August 2016 to September 2018 were enrolled.The patients were divided into the control group and the observation group according to the random number table,42 cases each.The control group was routinely treated with emergency treatment and anti-heart failure medication.The observation group was treated with tolvaptan at the same time.The efficacy and serum hs-CRP and NT-proBNP levels were compared between the two groups.Results The total effective rate of the observation group was 95.24%,which was higher than that of the control group 78.57%(P<0.05).After 1 week of treatment,the serum hs-CRP and NT-proBNP levels in the observation group were lower than those in the control group(P<0.05).Conclusion Tolvaptan in the treatment of acute myocardial infarction complicated with heart failure can improve the efficacy and improve serum hs-CRP and NT-proBNP.